Drugmakers are moving quickly to study whether cell therapy, already a proven treatment for certain blood cancers, can tamp down autoimmune conditions, too. Lupus, a chronic disease that can cause inflammation and pain across the body, is one of the industry’s top targets.
More than a dozen companies, Century among them, have cell therapies for lupus either in testing or set to soon begin testing. The development race was sparked by promising findings from a small study of so-called CAR-T therapy in people with lupus, which showed treatment could spur disease remission.
